Matthew Dohlman
Payments from drug & device makers
Across 779 payments — averaging $50.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- Johnson & Johnson$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Lilly USA, LLC$1K
- Amgen$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $6K from 18 others
What the payments were for
- Consulting fees$6002%
- Speaking & faculty fees$21,50055%
- Travel & lodging$1,9405%
- Food & beverage$14,86638%
- Education$5191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 150 | $26,193 |
| Johnson & Johnson(2 entities) | 54 | $1,885 |
| E.r. Squibb & Sons, L.L.C. | 78 | $1,562 |
| Lilly USA, LLC | 68 | $1,317 |
| Amgen | 57 | $1,247 |
| Regeneron Healthcare Solutions, Inc. | 45 | $1,189 |
| Pfizer | 59 | $1,084 |
| Novartis | 50 | $1,073 |
| Arcutis Biotherapeutics, Inc. | 56 | $964 |
| UCB, Inc. | 49 | $554 |
| LEO Pharma Inc. | 19 | $373 |
| Sanofi | 9 | $319 |
| Dermavant Sciences, Inc. | 22 | $309 |
| Sun Pharmaceutical Industries Inc. | 16 | $307 |
| Janssen Scientific Affairs, LLC | 2 | $260 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 13 | $255 |
| Organogenesis Inc. | 3 | $131 |
| Organon | 10 | $110 |
| Galderma Laboratories, L.p. | 6 | $97 |
| Biocon Biologics Inc | 3 | $72 |
| Kyowa Kirin, Inc. | 3 | $53 |
| Mayne Pharma Commercial LLC | 5 | $37 |
| Krystal Biotech Inc | 1 | $20 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,425 in reported general payments places this provider in the 95th percentile of 370 medical providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 29 | $608,209 |
| Dupixent PenDupilumab | 75 | $331,149 |
| Humira(Cf) PenAdalimumab | 44 | $301,430 |
| Dupixent SyringeDupilumab | 26 | $98,505 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $94,619 |
| Taltz AutoinjectorIxekizumab | 12 | $86,873 |
| Tacrolimus | 33 | $6,125 |
| Acitretin | 25 | $5,426 |
| Fluocinonide | 53 | $3,961 |
| Imiquimod | 132 | $3,715 |
| Triamcinolone Acetonide | 162 | $2,806 |
| Metronidazole | 42 | $2,800 |
| Ketoconazole | 165 | $2,477 |
| Calcipotriene | 13 | $2,282 |
| Fluorouracil | 28 | $2,041 |
Paid to pharmacies, not to this prescriber.
Other medical in Tulsa
- Tara LinvilleTulsa$19K
- Debra OdomTulsa$17K
- Kristen HaunTulsa$15K
- Monica AbbottTulsa$11K
- Ryan ChoplinTulsa$10K
- Julie McArthurTulsa$9K
- Ashley BiggsTulsa$8K
- Erin JonesTulsa$6K
- Caroline ParkerTulsa$6K
- J ThomasTulsa$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.